Therapeutic application of sodium pyruvate to patients of severe mitochondrial disorders

Therapeutic application of sodium pyruvate to patients of severe mitochondrial disorders - Sodium pyruvate therapy for mitochondrial disorders

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008341

Enrollment

Registered

2012-07-05

Start date

2012-07-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mitochondrial disorders

Interventions

Oral administration of sodium pyruvate supplied as a reagent.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who meet the criteria of mitochondrial disorders defined by Ministry of Health, Labour and Welfare of Japan. 2) Any inpatient, or outpatients who can visit at least once in two weeks, can participate. 3) Written informed consents are required in advance.

Exclusion criteria

Exclusion criteria: 1) Women who are pregnant, breastfeeding, or of possible pregnancy. 2) Patients who are judged to be inappropriate for any other reason by their doctor in charge.

Design outcomes

Primary

Measure	Time frame
Changes in scores of Mitochondrial Disease Adult Scale (NMDAS; for adults), or Newcastle Paediatric Mitochondrial Disease Scale (NPMDS; for children) before and after 6-month administration.	—

Secondary

Measure	Time frame
Reduction rate of lactate/pyruvate ratio in blood as effectiveness, and rate of adverse events as safety.	—

Countries

Japan

Contacts

Public ContactNobutsune Ishikawa

Hiroshima University Hospital Pediatrics

hiropedpyruvate@gmail.com082-257-5212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026